Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
about
Oxycodone DETERx®: A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic PainMarketed New Drug Delivery Systems for Opioid Agonists/Antagonists Administration: A Rapid OverviewSafety concerns with long-term opioid use.Formulation optimization of hot-melt extruded abuse deterrent pellet dosage form utilizing design of experiments.Abuse risks and routes of administration of different prescription opioid compounds and formulations.A review of abuse-deterrent opioids for chronic nonmalignant pain.Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendationsDesigning opioids that deter abuseAssessment of a formulation designed to be crush-resistant in prescription opioid abusers.A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users.Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.Current approaches in tamper-resistant and abuse-deterrent formulations.Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?Oxycodone combined with opioid receptor antagonists: efficacy and safety.Kitchen chemistry: A scoping review of the diversionary use of pharmaceuticals for non-medicinal use and home production of drug solutions.Abuse-deterrent formulations: part 1 - development of a formulation-based classification system.MEMS: Enabled Drug Delivery Systems.Development of an Abuse- and Alcohol-Resistant Formulation Based on Hot-Melt Extrusion and Film Coating.Contribution of hot-melt extrusion technology to advance drug delivery in the 21st century.An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia.Management of Patients on Abuse-Deterrent Opioids in the Ambulatory Surgery Setting.A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine-Morphine ARER.Designing a tool allowing for a standardized assessment of resistance to drug diversion.In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations.New immediate release formulation for deterring abuse of methadone.Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility.Abuse-deterrent opioids: an update on current approaches and considerations.Rat brain CYP2D activity alters in vivo central oxycodone metabolism, levels and resulting analgesia.The comparative pharmacokinetics of physical manipulation by crushing of Xtampza® ER compared with OxyContin®.Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone
P2860
Q28071792-C29D4A41-EDF2-4AFE-B2E1-081CA4AF62F8Q28079382-238438F2-397F-44E5-AA41-A317DF528621Q30251602-DB885255-521F-41BF-AFBA-5BB12FB293D3Q33998223-9F34937B-98D5-4A43-BDF6-C7C790981BE7Q35541054-FC081D06-6463-493F-9E7C-22F99E277DF1Q36137994-2F852F68-1C2C-4B52-BCFB-E29920DD6C49Q36389047-0E750C71-7C6B-4728-BE3C-65A3335E2AB5Q36415568-ED2E419B-3326-49A6-93E6-228F1C8BE896Q36845718-9F793D44-3C4A-4EF0-9E8F-D7EC8811FD62Q36878938-AF57383D-3500-4823-9D59-2CD085B2D043Q37457193-342EE026-A250-4E80-862A-9ED63BA7F309Q37954521-A2048DFA-3F0D-464E-832D-3AED6A7D0317Q38005778-BBC06180-FA0C-45E1-848D-71DC5C33B7FDQ38068507-33DF7203-80BB-40F5-B3C8-875231AAD225Q38093671-12477705-2A04-4B39-AB68-E1196CF7DC17Q38195230-D2564930-2B56-4505-8485-583BD4C4E06FQ38265486-DC760311-B018-42F6-B51B-C7E524268203Q38363665-5CEE1591-1A5E-4306-8A7F-72E1BEE5CB8AQ38619508-72B613A3-DFB2-440E-965D-A1E9009CCD13Q38737132-0979FD2D-4DA7-4BF6-9593-4DCE28A483B4Q38964492-B8C22DDC-E35C-432B-A669-822EED0D6540Q39157561-9B91054A-58E7-4D84-8E20-C0723618B02CQ39368338-85DA44A3-57CD-4017-9824-FA5DB3659CF6Q43317466-7FC1221E-FFC4-4481-8F69-1B4D07F369A9Q44349129-BC2CB352-4585-4FAA-BCE3-F915AC2AB497Q44966096-F1041BF8-82B6-4570-ACF2-C99355B14BA0Q44984523-29B8885A-6EF2-4AD9-8ED3-370E72935EC2Q47274936-142AFF8D-D5C6-4FDD-9335-BE7F15DA7BDAQ47561935-0D397112-F996-43C7-AA4D-FD7191DFDCACQ49682165-88B2CAAA-CA68-44F0-BC1A-66AD78FB5164Q57069317-9B35400D-F5DA-4775-811E-D49F2D5B43B2
P2860
Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
@en
Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
@nl
type
label
Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
@en
Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
@nl
prefLabel
Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
@en
Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
@nl
P1433
P1476
Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
@en
P2093
Lynn Webster
P304
P356
10.1111/J.1526-4637.2009.00672.X
P478
10 Suppl 2
P577
2009-07-01T00:00:00Z